Urolithin A Supplementation in Middle-aged Adults With Obesity
Launched by UNIVERSITY OF OKLAHOMA · Jun 26, 2023
Trial Information
Current as of May 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a dietary supplement called urolithin A to see if it can improve blood flow in middle-aged adults who are dealing with obesity. Researchers want to find out if taking this supplement daily for four weeks can help increase blood flow in both large and small blood vessels. Participants will need to visit the study site twice for tests that check their blood vessels, answer some questions, and provide a blood sample. Some participants will take the urolithin A supplement, while others will receive a placebo, which is a pill that looks the same but contains no active ingredients.
To join the study, you need to be between 40 and 64 years old and have obesity, which means your body mass index (BMI) is 30 or higher. You also need to be able to read, write, and speak English and give your consent to participate. Unfortunately, if you are pregnant, have certain health conditions like diabetes or significant heart issues, or have a history of cognitive impairment, you may not be eligible. If you decide to participate, you'll be helping researchers learn more about how urolithin A could potentially support better blood flow in people with obesity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age: 40-64 years old, inclusive
- • Obesity \[BMI ≥30 kg/m2\]
- • Ability to read, write, and speak English
- • Competence to provide written informed consent
- Exclusion Criteria:
- • Pregnant or breastfeeding women, or women who intend to become pregnant within the study period
- • History of uncontrolled hypertension
- • History of uncontrolled type 1 or type 2 diabetes mellitus
- • Significant cardiac disease or chest pain in the last 6 months
- • History of untreated depression or anxiety
- • History of cognitive impairment
- • History of uncontrolled significant GI disease (e.g., IBS, Crohn's disease)
- • Allergy or intolerance to one or more of the intervention components
- • Undergoing treatment for active cancer
- • History of neurodegenerative disorders (e.g., multiple sclerosis)
- • Presence of any condition affecting swallowing ability
- • Any other medical condition that the investigators deem would adversely affect the participant's safety or ability to complete the study
About University Of Oklahoma
The University of Oklahoma, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials and research initiatives. With a robust network of interdisciplinary experts and state-of-the-art facilities, the university fosters an environment that promotes scientific discovery and the development of new treatments. Its commitment to patient-centered research ensures that clinical trials not only adhere to the highest ethical standards but also aim to address pressing health challenges. By collaborating with various stakeholders, including industry partners and healthcare providers, the University of Oklahoma seeks to translate research findings into tangible benefits for communities, ultimately enhancing the quality of care and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oklahoma City, Oklahoma, United States
Oklahoma City, Oklahoma, United States
Patients applied
Trial Officials
Andriy Yabluchanskiy, MD, PhD
Principal Investigator
University of Oklahoma Health Science Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported